Ahmed Abdelhafez

Ahmed Abdelhafez

Auto-generated profile, based on publicly available information

Ahmed Abdelhafez

Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
MAMesfer Alfadhel
Mesfer Alfadhel
CFChris Frawley
Chris Frawley
JSJanarthanan Sathananthan
Janarthanan Sathananthan
OBOle de Backer
Ole de Backer
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.
DBDaniel J. Blackman
Daniel J. Blackman
BACKGROUND: Redo transcatheter aortic valve implantation (TAVI) is increasing as patients outlive their transcatheter heart valves (THVs) and present with bioprosthetic valve failure. The Lotus mechanically expanded THV has unique design characteristics, which have specific implications for Redo TAVI. METHODS: The design features of the Lotus valve and their relevance to Redo TAVI were reviewed. Bench-top analysis of Redo TAVI was performed using different contemporary THVs. Procedural and outcome data were obtained from 10 patients who had undergone Redo TAVI for Lotus bioprosthetic valve failure in 5 centers. Recommendations for performing Redo TAVI in Lotus are made, based on these findings. RESULTS: The Lotus leaflets extend from the frame inflow, with a Neoskirt of only 13 mm, hence a low risk of coronary obstruction during Redo TAVI. The Lotus frame posts prevent full apposition of the Redo prosthesis in the upper part of the frame, while implantation of the Redo THV above the Lotus inflow leads to inadequate apposition of the Lotus leaflets. Inflow-to-inflow positioning is therefore recommended for effective sealing and leaflet pinning. The Lotus locking mechanism prevents overexpansion of the frame, limiting Redo THV oversizing. Redo TAVI was favorable with SAPIEN 3, Evolut, and Navitor THVs on bench-top analysis but not with ACURATE Neo 2 due to the upper crowns and short stent preventing inflow-to-inflow deployment. Case review demonstrated satisfactory outcomes in 10 patients treated with Evolut (n=6), SAPIEN 3 (n=3), and Portico (n=1) valves, with no mortality, major morbidity, or coronary obstruction. Three patients had residual mean gradient ≥20 mm Hg, including 2 of 3 SAPIEN cases. Guidance on procedural planning, valve choice, sizing, and positioning is provided. CONCLUSIONS: Redo TAVI in Lotus requires an understanding of unique design characteristics, and adherence to key procedural recommendations, but can be safely and effectively performed with most contemporary valve types.

8 June 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
JLJohannes Rotta detto Loria
Johannes Rotta detto Loria
ODOliver Dumpies
Oliver Dumpies
AAAhmed Abdelhafez
Ahmed Abdelhafez
IRInes Richter
Ines Richter
NMNicolas Majunke
Nicolas Majunke
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.
Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is an established therapy for failed bioprosthetic valves but carries risks for coronary obstruction and subclinical leaflet thrombosis, characterized by hypoattenuated leaflet thickening (HALT) on multidetector computed tomography. Intentional leaflet modification techniques, such as BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction), have been developed to prevent coronary obstruction, but their impact on leaflet thrombosis remains unclear. The aim of this study was to evaluate the association of intentional leaflet modification with the incidence of HALT in patients undergoing ViV TAVR. In a retrospective analysis of 141 patients undergoing ViV TAVR with postprocedural multidetector computed tomography, 61 patients received leaflet modification, and 80 underwent standard ViV TAVR without leaflet modification. Baseline characteristics, post-TAVR computed tomographic findings including HALT, and other procedural outcomes were compared. A sensitivity analysis stratified outcome by transcatheter heart valve type. Predictors of HALT were assessed using multivariable logistic regression with clinically relevant covariates. Leaflet modification was more frequently performed in female patients (62.3% vs 45%; P = 0.04) and those with small (≤21 mm) prosthetic valves (50% vs 22.5%; P < 0.001). Patients undergoing leaflet modification had significantly lower postprocedural mean transvalvular gradients (13 ± 6 mm Hg vs 18 ± 9 mm Hg; P < 0.001) and a reduced incidence of HALT (19.7% vs 40%; P < 0.01) compared with those without leaflet modification. These findings persisted after the analysis was restricted to self-expanding transcatheter heart valves. HALT involving multiple leaflets was numerically less common with leaflet modification (33.3% vs 65.6%; P = 0.054), and thrombosis predominantly affected nonlacerated cusps (66.6% vs 33.3%). No cases of HALT were observed in patients undergoing dual-leaflet modification. Reduced leaflet motion was identified in one-third of patients with HALT, with no significant difference between groups. In patients undergoing ViV TAVR, intentional leaflet modification is associated with a significantly reduced incidence of HALT, suggesting a protective association with subclinical leaflet thrombosis. These results support a potentially hemodynamic benefit of leaflet modification beyond coronary obstruction prevention.

8 June 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
AAAhmed Abdelhafez
Ahmed Abdelhafez
NLNiklas Lankisch
Niklas Lankisch
GIGianmarco Iannopollo
Gianmarco Iannopollo
ODOliver Dumpies
Oliver Dumpies
JLJohannes Rotta detto Loria
Johannes Rotta detto Loria
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.
Coronary obstruction (CO) during transcatheter aortic valve replacement (TAVR) is rare but potentially fatal. Computed tomography (CT)-based risk assessment algorithms aim to identify high-risk patients, but their utility remains underexplored. The aim of this study was to examine the clinical utility of a CT-derived algorithm for predicting CO during TAVR and identify predictors of CO despite coronary protection (CP). In this prospective study, 164 patients at risk for CO during TAVR were enrolled. Preprocedural CT was used to classify risk using a published algorithm. A novel volumetric parameter, valve-to-coronary volume (VTCV), was calculated in high-risk cases using sinus width and valve-to-coronary (VTC) distance. The decision to use CP was left to the heart team. Clinical endpoints followed Valve Academic Research Consortium 3 definitions. According to the CT-based algorithm, 58.5% of patients (96 of 164) were at low risk, 24.4% (40 of 164) at intermediate risk, and 17.1% (28 of 164) at high risk. CP was performed in 12.8% of low-risk patients (16 of 125), 52.8% of intermediate-risk patients (28 of 53), and 93.9% of high-risk patients (31 of 33). All CO events (n = 7) occurred in the high-risk group. VTC distance and VTCV were significantly lower in patients with CO (P = 0.006 and P = 0.005, respectively). VTCV independently predicted CO (area under the curve, 0.841; 95% CI: 0.702-0.979; P < 0.001), outperforming VTC distance alone. The predictive value of VTCV was validated in an external cohort including 11 European centers. A CT-based algorithm stratifies patients into 3 CO risk categories, though the decision for CP in clinical practice seems to incorporate additional clinical and procedural variables. Although CP reduces CO risk, its efficacy is limited in patients with very small VTCV, which can be predicted preprocedurally via CT. (Leipzig TAVR Registry; NCT05015452).

23 October 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
JLJohannes Rotta detto Loria
Johannes Rotta detto Loria
AAAhmed Abdelhafez
Ahmed Abdelhafez
SDSteffen Desch
Steffen Desch
HTHolger Thiele
Holger Thiele
MAMohamed Abdel‐Wahab
Mohamed Abdel‐Wahab
Transcatheter aortic valve implantation (TAVI) has become a well‐established treatment option for elderly patients with symptomatic severe aortic stenosis. Coronary artery anomalies are an infrequent finding and there have only been few anecdotal reports of patients with coronary anomalies treated with TAVI. We here present a comprehensive overview of existing reports in addition to an own case series to facilitate better understanding of this potentially challenging clinical scenario.

8 June 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
IRInes Richter
Ines Richter
AAAhmed Abdelhafez
Ahmed Abdelhafez
JLJonas Lanz
Jonas Lanz
MTMaurizio Taramasso
Maurizio Taramasso
AUAxel Unbehaun
Axel Unbehaun
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.
Transcatheter electrosurgical leaflet splitting prevents coronary artery obstruction (CAO) following transcatheter aortic valve replacement (TAVR), particularly in valve-in-valve interventions. Morphologic and fluoroscopic differences between stented and stentless valves may affect outcomes, but comparative data are limited. The aim of this study was to compare procedural characteristics and outcomes of BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic CAO) and TAVR in stented vs stentless surgical bioprosthetic valves. A total of 131 patients undergoing BASILICA and valve-in-valve TAVR from the multicenter EURO-BASILICA registry were included. Patients were stratified by valve type (stented vs stentless), and outcomes were described according to Valve Academic Research Consortium 3 recommendations. Overall, 115 patients (87.8%) had stented valves and 16 (12.2%) had stentless valves. Risk for CAO was comparable, but stentless valves had longer leaflets (17.0 vs 14.0 mm; P < 0.001). Procedures in stentless valves required more contrast medium (174.0 vs 91.0 mL; P < 0.001) and longer fluoroscopy (61.7 vs 41.0 min; P = 0.023) and showed a trend toward longer procedure time. Technical success was similar, but stentless valves were associated with a significantly higher rate of target leaflet-related CAO (44.4% vs 7.1%; P < 0.001), which was mainly partial and non-flow-limiting (33.3% vs 3.9%; P < 0.001). In-hospital complications and 30-day outcomes were similar. No late CAO or myocardial infarction occurred during 1-year follow-up. BASILICA is technically feasible for both stented and stentless valves. However, stentless valves had a higher rate of partial CAO after BASILICA and TAVR and may therefore require additional or alternative coronary artery protection measures in selected patients.

8 June 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
AAAhmed Abdelhafez
Ahmed Abdelhafez
AKArif A. Khokhar
Arif A. Khokhar
ABAlessandro Beneduce
Alessandro Beneduce
OBOle de Backer
Ole de Backer
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.